POST Online Media Lite Edition



 

Medivation rejects Sanofi's $9.3 billion bid

Staff writer |
Medivation said it rejected Sanofi's $9.3 billion takeover offer, claiming that the French drugmaker's proposal "undervalues" the cancer-treatment company.

Article continues below






The move by Medivation comes one day after Sanofi said it made an unsolicited offer, which was its latest effort to expand its cancer-treatment business.

Medivation said its board had unanimously rejected the Sanofi's offer and that the proposal would deny its shareholders of the value in its late-stage pipeline, as well as its flagship oncology drug, Xtandi.

Sanofi responded Friday by saying it remained "committed" to the transaction and looked forward to "engaging directly with Medivation shareholders."

Sanofi's offer of $52.50 a share was a 50% premium on Medivation's average share price for the two months before takeover speculation emerged, though lower than Medivation's current share price, which was buoyed by takeover speculation.


What to read next

Medivation sets date for shareholder consent on board revamp
Sanofi to Medivation: Talk to us or we'll replace your board
Sanofi starts action to remove all Medivation directors